
PainReform Ltd. PRFX
€ 0.69
1.3%
PainReform Ltd. Langfristiger Schuldenstrom | PRFX
Langfristiger Schuldenstrom Jährlich PainReform Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21 K | 45 K | 56 K | - | - | - | - | - | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 56 K | 21 K | 40.7 K |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Amgen
AMGN
|
135 M | $ 465.26 | 0.01 % | $ 250 B | ||
|
Biogen
BIIB
|
80.4 M | $ 253.37 | -0.59 % | $ 37.1 B | ||
|
Edesa Biotech
EDSA
|
19.9 K | $ 2.01 | -19.28 % | $ 11.4 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
439 K | $ 15.12 | -0.72 % | $ 978 M | ||
|
Achieve Life Sciences
ACHV
|
61 K | $ 6.78 | 0.89 % | $ 296 M | ||
|
Fulcrum Therapeutics
FULC
|
2.4 M | $ 3.72 | -0.13 % | $ 236 M | ||
|
Immutep Limited
IMMP
|
205 K | $ 3.53 | -7.11 % | $ 5.14 B | ||
|
Iovance Biotherapeutics
IOVA
|
4.04 M | $ 8.09 | -1.04 % | $ 2.89 M | ||
|
Evogene Ltd.
EVGN
|
716 K | $ 0.37 | 28.7 % | $ 2.91 M | ||
|
Armata Pharmaceuticals
ARMP
|
4.56 M | $ 3.71 | -2.5 % | $ 134 M | ||
|
Axsome Therapeutics
AXSM
|
434 K | $ 141.12 | 5.34 % | $ 7.02 B | ||
|
Keros Therapeutics
KROS
|
2.41 M | $ 9.32 | 1.64 % | $ 347 M | ||
|
Champions Oncology
CSBR
|
1.52 M | $ 4.85 | 0.21 % | $ 67.1 M | ||
|
Fennec Pharmaceuticals
FENC
|
2 K | $ 10.6 | -2.12 % | $ 303 M | ||
|
Forte Biosciences
FBRX
|
416 K | $ 76.99 | 0.03 % | $ 997 M | ||
|
Immunic
IMUX
|
470 K | $ 8.06 | 1.26 % | $ 1.25 B | ||
|
DiaMedica Therapeutics
DMAC
|
101 K | $ 9.7 | 0.47 % | $ 456 M | ||
|
Grifols, S.A.
GRFS
|
117 M | $ 8.74 | 0.63 % | $ 5.94 B | ||
|
Incyte Corporation
INCY
|
5.7 M | $ 120.28 | -1.32 % | $ 23.5 B | ||
|
AC Immune SA
ACIU
|
852 K | $ 2.32 | -4.92 % | $ 234 M | ||
|
Aldeyra Therapeutics
ALDX
|
281 K | $ 0.64 | 0.53 % | $ 38.4 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Precision BioSciences
DTIL
|
1.51 M | $ 9.47 | -2.17 % | $ 121 M | ||
|
AIM ImmunoTech
AIM
|
250 K | $ 0.14 | -11.15 % | $ 227 K | ||
|
Ascendis Pharma A/S
ASND
|
14.2 M | $ 256.21 | -1.4 % | $ 15.5 B | ||
|
ANI Pharmaceuticals
ANIP
|
1.92 M | $ 71.31 | 5.19 % | $ 1.43 B | ||
|
Actinium Pharmaceuticals
ATNM
|
711 K | $ 1.56 | 1.3 % | $ 48.7 M | ||
|
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.31 | -0.76 % | $ 349 M | ||
|
Monopar Therapeutics
MNPR
|
90.6 K | $ 71.42 | -3.16 % | $ 529 M | ||
|
BridgeBio Pharma
BBIO
|
6.19 M | $ 78.67 | 0.95 % | $ 15.1 B | ||
|
BioCryst Pharmaceuticals
BCRX
|
317 K | $ 7.53 | -1.38 % | $ 1.58 B | ||
|
Bicycle Therapeutics plc
BCYC
|
2.55 M | $ 3.68 | -2.39 % | $ 255 M | ||
|
Coherus BioSciences
CHRS
|
1.83 M | $ 0.64 | -21.66 % | $ 75 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 27.45 | 4.77 % | $ 3.49 B | ||
|
Cellectis S.A.
CLLS
|
7.7 M | $ 1.12 | -0.45 % | $ 112 M | ||
|
BeyondSpring
BYSI
|
320 K | $ 0.6 | -2.21 % | $ 24.7 M | ||
|
Alkermes plc
ALKS
|
6.75 M | $ 46.48 | 0.67 % | $ 7.66 B | ||
|
Altimmune
ALT
|
256 K | $ 1.94 | -8.51 % | $ 171 M | ||
|
Cardiff Oncology
CRDF
|
730 K | $ 0.79 | -0.77 % | $ 52.8 M | ||
|
Citius Pharmaceuticals
CTXR
|
88.3 K | $ 0.5 | -5.43 % | $ 5.53 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
4.21 M | $ 9.41 | -0.84 % | $ 258 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
7.29 M | $ 49.04 | -0.41 % | $ 6.56 B | ||
|
Atara Biotherapeutics
ATRA
|
1.03 M | $ 8.18 | -0.73 % | $ 103 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
1.07 M | $ 16.3 | -1.93 % | $ 2.19 B | ||
|
Cullinan Management
CGEM
|
780 K | $ 11.34 | -3.32 % | $ 683 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 87.2 | -0.36 % | $ 21.1 B | ||
|
Collegium Pharmaceutical
COLL
|
1.41 M | $ 24.47 | -0.97 % | $ 775 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
1.63 M | $ 3.95 | 12.07 % | $ 52.6 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
235 K | $ 1.21 | -11.68 % | $ 55.3 M | ||
|
AnaptysBio
ANAB
|
2.16 M | $ 48.4 | 0.9 % | $ 1.4 B |